Linical Co

Linical Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Linical Co (2183.T) as of Nov 10, 2026 is -2.07 B JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -215.45 M JPY — a change of 862.20% (lower).

EBITDA

-2.07 BJPY

YoY

862.20%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Linical Co is 2026 -2.07 B JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Linical Co was 2025 -215.45 M JPY. It decreases by 862.20% lower compared to the previous year.

The Linical Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
1.53 B JPY
Jan 1, 2020
1.29 B JPY
Jan 1, 2021
681.44 M JPY
Jan 1, 2022
1.36 B JPY
Jan 1, 2023
1.58 B JPY
Jan 1, 2024
1.07 B JPY
Jan 1, 2025
-215.45 M JPY
Jan 1, 2026
-2.07 B JPY
The Linical Co EBITDA history
YEAREBITDAYoY
-2.07 BJPY+862.20%
-215.45 MJPY-120.08%
1.07 BJPY-31.88%
1.58 BJPY+16.03%
1.36 BJPY+99.24%
681.44 MJPY-47.05%
1.29 BJPY-15.96%
1.53 BJPY-17.08%
1.85 BJPY-16.75%
2.22 BJPY+10.22%
2.01 BJPY+129.54%
876.72 MJPY+24.15%
706.20 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Linical Co Stock analysis

What does Linical Co do? Linical Co., Ltd. generates revenue through two distinct business segments, the CRO segment and the Pharmaceutical Sales Support segment. The CRO segment provides contract monitoring, quality management, and consulting services specifically for phase II and phase III in drug development processes. These services are delivered to pharmaceutical companies as part of pharmaceutical contract research projects. The Pharmaceutical Sales Support segment focuses on the downstream market by providing pharmaceutical sales support for medical institutions. The company operates these businesses from its headquarters in Osaka, Osaka-Fu, leveraging its workforce of 759 full-time employees to deliver these specialized services. Linical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linical Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Linical Co is -2.07 B JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Linical Co changed from -215.45 M JPY to -2.07 B JPY, representing a 862.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Linical Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Linical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Linical Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Linical Co